BMS-582949

BMS-582949 (compound 7k) is an orally active and highly selective p38α MAP kinase inhibitor, with IC50 values of 13 nM for p38α, and 50 nM for cellular TNFα. BMS-582949 can be used for research on rheumatoid arthritis[1].

Product Specifications

CAS Number

[623152-17-0]

UNSPSC

12352005

Hazard Statement

H360-H373

Target

P38 MAPK

Type

Reference compound

Related Pathways

MAPK/ERK Pathway

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/bms-582949.html

Solubility

10 mM in DMSO

Smiles

O=C(NCCC)C1=CN(N=CN=C2NC3=CC(C(NC4CC4)=O)=CC=C3C)C2=C1C

Molecular Formula

C22H26N6O2

Molecular Weight

406.48

Precautions

P260-P280-P405-P501

References & Citations

[1]Liu C, et al. Discovery of 4- (5- (cyclopropylcarbamoyl) -2-methylphenylamino) -5-methyl-N-propylpyrrolo[1,2-f][1,2,4]triazine-6-carboxamide (BMS-582949), a clinical p38α MAP kinase inhibitor for the treatment of inflammatory diseases. J Med Chem. 2010 Sep 23;53 (18) :6629-39.